Conference Reports for NATAP

Back

AASLD (American Association for the Study of Liver Diseases)   Nov 2-5, 2002, Boston, MA     Treating Patients with Decompensated Cirrhosis: 20% sustained response rate - (06/30/03)   HCV in HIV Coinfection and in IVDUs - (11/25/02)   HCV Viral Kinetics and Early Response Predicting Sustained Response - (11/19/02)   IVDUs, Depression & Mental/Emotional Issues in HCV Therapy Can Be Successfully Addressed - (11/19/02)   Treatment for Hepatitis B Looks Promising - (11/19/02)   Twice Weekly Injections of PegIntron - (11/13/02)   Pegasys plus Ribavirin in African-Americans - (11/13/02)   Hepatitis C Found In Cerebrospinal Fluid - (11/13/02)   Orally available Hepatitis C Virus (HCV) Protease Inhibitor (BILN 2061, Boehringer Ingelheim Pharma) Demonstrates Potent Anti-viral Activity in Persons Infected with HCV Genotype 1 - Written by Mark Sulkowski, MD, Johns Hopkin University School of Medicine - (11/8/02)   Ist HCV Protease Inhibitor: 2nd study presented at AASLD - (11/8/02)   Hard to Treat Patients: African Americans and previous nonresponders - (11/7/02)   Predictive Value of Early Virologic Response - (11/7/02)   Retreatment of Nonresponders & Relapsers and Maintenance Therapy - (11/7/02)   1st HCV protease Inhibitor: effective over 2-day study - (11/7/02)   Does HIV Accelerate HCV Progression? - (11/5/02)   Liver Transplantation in HIV and HCV Coinfected Patients - (11/3/02)   EPOETIN ALFA (PROCRIT) ONCE WEEKLY MAINTAINS RIBAVIRIN DOSE IN HEPATITIS C VIRUS (HCV)-INFECTED PATIENTS TREATED WITH COMBINATION THERAPY: interim results - (11/3/02)   NEW HCV DRUGS IN EARLY DEVELOPMENT - (11/3/02)   HCV Viral Kinetics During Therapy - (11/3/02)